Thrombolysis-related hemorrhagic infarction: A marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion

Stroke

Volumn 33, Issue 6, 2002, Pages 1551-1556

  Molina, Carlos A ^a   Alvarez Sabín, José ^a   Montaner, Joan ^a   Abilleira, Sonia ^a   Arenillas, Juan F ^a   Coscojuela, Pilar ^a   Romero, Francisco ^a   Codina, Agusti ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Hemorrhage; Reperfusion; Thrombolysis; Ultrasonography

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN PERFUSION; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPERFUSION INJURY; SCORING SYSTEM; STROKE;

ADULT; AGED; AGED, 80 AND OVER; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; DEMOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPERFUSION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0036284568     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000016323.13456.E5     Document Type: Article

References (39)

1. Tissue plasminogen activator for acute ischemic stroke
2. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS)
3. Ramdomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II)
4. Hemorrhagic transformation within 36 hours of a cerebral infarct: Relationship with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort
5. Hemorrhagic transformation of ischemic brain tissue: Asymptomatic or symptomatic
6. Spontaneous middle cerebral artery reperfusion in ischemic stroke: A follow-up study with transcranial Doppler
7. Transcranial Doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke
8. Acute stroke: Usefulness of early CT findings before thrombolytic therapy
9. Thrombolytic agents in the treatment of stroke
10. Hemorrhagic transformation in acute ischemic stroke
11. Improved reliability of the NIH stroke scale using video training
12. Myths regarding NINDS rtPA Stroke Trial: Setting the record straight
13. Interobserver agreement for the assessment of handicap in stroke patients
14. Intracerebral hemorrhage after intravenous t-PA for ischemic stroke
15. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke
16. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)
17. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction
18. Hemorrhagic transformation in focal cerebral ischemia: Influence of time to artery reopening and tissue plasminogen activator
19. Early (1h) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats
20. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke
21. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: A case-control study
22. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke
23. Relationship between apparent diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke
24. Prediction of hemorrhagic transformation following acute stroke: Role of diffusion- and perfusionweighted magnetic resonance imaging
25. Hemorrhagic infarcts
26. Ischaemic damage of brain microvessels: Inherent risks for thrombolyfic treatment in stroke
27. The rtPA (alteplase) 0-to 6 hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study
28. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II trial
29. Hemorrhage after an acute ischemic stroke
30. Hemorrhagic transformation in acute ischemic stroke: The MAST-E study
31. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
32. Reperfusion and metabolic recovery of brain tissue and clinical outcome after ischemic stroke and thrombolytic therapy
33. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk
34. Prediction of hemorrhagic complications after thrombolytic therapy for middle cerebral artery occlusion: Value of pre- and post-therapeutic computed tomographic findings and angiographic occlusive site
35. Direct percutaneous transluminal angioplasty for middle cerebral artery occlusion
36. Delayed rtPA treatment in rat embolic stroke model: Diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging
37. Hemorrhagic transformation of brain infarct: Predictability in the first 5 hours from stroke onset and influence on clinical outcome
38. Hemorrhagic transformation: Guilt by association?
39. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI